|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-9-9
|
|
pubmed:abstractText |
Intraocular methotrexate has been safely used in eyes with primary CNS lymphoma (PCNSL), and in eyes with uveitis and proliferative diabetic retinopathy. Dosing in silicone-filled eyes was reduced from a standard 400 microg intravitreal injection due to concerns of toxicity. The present study reports the visual results of non-PCNSL, silicone-filled eyes treated with intravitreal methotrexate using cumulative dosages ranging from 200 microg to 1,200 microg.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1539-2864
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1082-6
|
|
pubmed:meshHeading |
pubmed-meshheading:18779714-Cohort Studies,
pubmed-meshheading:18779714-Diabetic Retinopathy,
pubmed-meshheading:18779714-Dose-Response Relationship, Drug,
pubmed-meshheading:18779714-Eye,
pubmed-meshheading:18779714-Eye Diseases,
pubmed-meshheading:18779714-Follow-Up Studies,
pubmed-meshheading:18779714-Humans,
pubmed-meshheading:18779714-Injections,
pubmed-meshheading:18779714-Methotrexate,
pubmed-meshheading:18779714-Ocular Hypotension,
pubmed-meshheading:18779714-Retinal Detachment,
pubmed-meshheading:18779714-Retrospective Studies,
pubmed-meshheading:18779714-Silicones,
pubmed-meshheading:18779714-Uveitis,
pubmed-meshheading:18779714-Visual Acuity,
pubmed-meshheading:18779714-Vitreoretinopathy, Proliferative,
pubmed-meshheading:18779714-Vitreous Body
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The safety of intraocular methotrexate in silicone-filled eyes.
|
|
pubmed:affiliation |
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA. hardwig.paul@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
